person
as of 2026-07-01Erik Johnsen, MD, PhD
at a glance
Roles: Principal Investigator, Author
KOL signal score 15
6 publications · 4 high-value
Cross-drug reach: 1 competitor drugs
Synthesized from structured facts only — each point cited above.
Profile
Affiliation
Haukeland University Hospital
Roles
Principal Investigator, Author
KOL signal
15
Publications
6 (4 high-value)
Trial investigator
no
Publishes on
1 drugs
Trials led
1
The Norwegian Prednisolone in Early Psychosis Study
NCT03340909Phase 2Terminated
Publications & congress
6
Levels of and changes in psychosis symptoms and clinical insight: Exploring the impact of differential antipsychotic mechanisms.
Psychiatry research · 2026 · high-value
Remission in schizophrenia spectrum disorders: A randomized trial of amisulpride, aripiprazole and olanzapine.
Schizophrenia research · 2024 · high-value
Antidepressive Effectiveness of Amisulpride, Aripiprazole, and Olanzapine in Patients With Schizophrenia Spectrum Disorders: A Secondary Outcome Analysis of a Pragmatic, Randomized Trial (BeSt InTro).
Journal of clinical psychopharmacology · 2023 May-Jun 01 · high-value
Does drug use affect the efficacy of amisulpride, aripiprazole and olanzapine in patients with schizophrenia spectrum disorders? Results from a pragmatic, randomised study.
General hospital psychiatry · 2023 · high-value
Cytokine changes during a 12-month pragmatic randomized trial in schizophrenia spectrum disorders comparing amisulpride, aripiprazole and olanzapine.
Psychiatry research · 2026
Three-week effect of amisulpride, aripiprazole, and olanzapine on gene expression in peripheral blood in individuals with schizophrenia spectrum disorders.
The international journal of neuropsychopharmacology · 2026
Facts & assertions
0 sourced
No assertions recorded for this entity.
relationships
The graph out of here
publishes on
drug
PRINCIPAL_INVESTIGATOR